The U.S. Most Favored Nation (MFN) Executive Order could upend global drug pricing as we know it. Some manufacturers are now vowing to launch only at U.S. prices, daring the rest of the world to follow.
What happens if the MFN Executive Order sets the framework for pharmaceutical pricing in the U.S.?
- How will payers and governments in other countries react?
- How might trade policy be used to enforce or react to changes in multinational company pricing strategies?
- Will this open access to China to undercut the US in pricing and establish access agreements?
- Could the U.S. actually raise prices in other countries? Or will this policy mean not launching in certain countries?
Join us for a candid CRA-moderated breakfast conversation during the J.P. Morgan Conference on the ripple effects, power shifts, and opportunities created if the world’s largest market attempts to rewrite the rules on pharmaceutical pricing.
Speakers:
Richard Torbett, PhD
Dr. Torbett MBE is Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), a role he has held since 2020. With nearly two decades of experience in the pharmaceutical sector and a background in economics, innovation, and healthcare policy, he has worked internationally at Pfizer, EFPIA, and in UK government roles. Richard serves on several national life sciences boards and was awarded an MBE in 2024 for his services to the industry.
Erin Trish, PhD
Erin is co-director of the USC Schaeffer Center for Health Policy & Economics and an associate professor at the USC Mann School of Pharmacy. Her research examines the intersection of public policy and health care markets, with work on Medicare, the pharmaceutical supply chain, and surprise medical bills. Widely published and funded by leading foundations, she has testified before Congress and federal agencies, and in 2018 received the Seema Sonnad Emerging Leader in Managed Care Research Award.
Jürgen Wasem
Juergen is Professor of Health Services Management at the University of Duisburg-Essen, where he leads programs in health economics and management. He has served in key roles within the German health care system, including chairing arbitration boards on drug pricing, digital health app reimbursement, and physician fee schedules. With dual PhDs in health economics and public health, he is a recognized expert advising policymakers on health care financing, drug policy, and hospital systems.
Moderator:
Kirsten Axelsen
Kirsten is a Senior Policy Advisor at Charles River Associates. She works with leaders in healthcare helping to develop business practices that lead to greater access to affordable medicines, positive public perception, and sustained profitability to support investment in the next generation of innovation.
To learn more and request a registration, click here.
